All India Institute of Medical Science expands cancer care with advanced treatment devices from Elekta

GURGAON, India, October 18, 2016 – Elekta (EKTA-B.ST) announces that All India
Institute of Medical Science (AIIMS) will acquire seven Versa
HD™ (http://www.elekta.com/versahd) linear accelerators and six
microSelectron® (http://www.elekta.com/MicroSelectron) brachytherapy systems.
The investment supports AIIMS’s current phase of sustained expansion, which
represents India’s largest public investment in health sector.
The agreement also includes Elekta’s Monaco® (http://www.elekta.com/monaco)
treatment planning system and MOSAIQ® (http://www.elekta.com/mosaiq) radiation
oncology information system, as well as service for both hardware and software.

Charles Schanen, Senior Vice President, Region Asia Pacific says: “We are very
happy to support AIIMS as it introduces sophisticated cancer treatment
technology to treat this widespread disease.

“Versa HD, the most advanced linear accelerator, will be an excellent asset as
it is capable of delivering stereotactic body radiotherapy (SBRT) and
radiosurgery (SRS). Cervical cancer is ranked as the most frequent type for
women in India. Brachytherapy (internal radiotherapy) is one of the most common
methods used to treat cancer of the cervix and our microSelectron remote
afterloading platform should benefit thousands of Indian women suffering from
this cancer.”

Every year approximately 4,000 new patients consult AIIMS to receive various
radiotherapy treatments. Elekta’s agreement with AIIMS covers seven sites across
India.

Manikandan Bala, Managing Director for Elekta in India says: “According to the
International Agency for Research on Cancer, India has more than one million new
cancer cases every year. However, the country is making great progress in
developing its cancer care and we are honored that AIIMS has chosen Elekta to
contribute to this. This agreement demonstrates Elekta’s commitment to making
radiation therapy available where it is needed most.”

The order was booked in the second quarter of Elekta’s fiscal year and the first
shipments will begin in March 2017.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to
the EU Market Abuse Regulation, the Securities Markets Act and/or the Financial
Instruments Trading Act. The information was submitted for publication at 07:30
CET on October 18, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,600 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.